NCT04471961: ALADIN

Analyse of Tumour and Constitutional DNA for the Study of the Determinism in Child Neoplasia

Active, enrolled NA Last updated 30 September 2025

What this trial tests

NA trial testing Exome sequencing in pediatrics cancers in Pediatric Tumor in 100 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

9 July 2020

Primary endpoint
12 February 2025

31 December 2026

Quick facts

Lead sponsor	University Hospital, Montpellier
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	100
Start date	9 July 2020
Primary completion	12 February 2025
Estimated completion	31 December 2026
Sites	1 location across France

Drugs / interventions tested

• Exome sequencing in pediatrics cancers

Conditions studied

• Pediatric Tumor — all drugs for Pediatric Tumor →
• Familial Cancer — all drugs for Familial Cancer →
• Solid Tumor, Childhood — all drugs for Solid Tumor, Childhood →
• Hematological Tumor — all drugs for Hematological Tumor →

Sponsor

University Hospital, Montpellier

Who can join

Eligibility, any sex, with Pediatric Tumor or Familial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background. Cancer is the leading cause of death by disease in children. Most pediatric tumors differ from adult tumors in terms of biological and clinical characteristics. In children, the part of genetic determinism could be higher since the role of environmental factors may be less pronounced than in adults and that a young age at onset is a main feature of genetic cancer predisposition. Recent studies suggested that a number of genetic predisposition remains to be characterized.

Methods. Trio-Based whole exome sequencing of germline DNA from patients (children and adults diagnosed with cancers between 0 and 17 years) and parents will be performed prospectively in a multicentric study including 40 unselected cases of malignant tumor. Participating hospitals will include the CHU of Montpellier, the CHU de Nice and the AP-HP. Tumor analysis will include whole exome analysis and transcriptome for the identification of therapeutic target and contribute to confirm potential link between constitutive mutations and tumor phenotype (such as loss of expression, loss of heterozygosity).

Perspectives. This pediatric oncology study proposing a global approach integrating trio-based whole exome sequencing, somatic DNA and RNA analysis will improve the recognition of genetic predisposition and the characterization of target therapies in children with cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.